WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation Committee”)
Interim Analysis from Phase 2 Trial Demonstrates Compelling Anti-Tumor Activity in Patients with Frontline and Relapsed/Refractory BPDCN; No New Safety Signals Identified Enrollment Continues in Frontline CADENZA Cohort; Top-Line Pivotal Data Expected in 2024 WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically Meaningful Improvements in Progression Free Survival and Overall Survival Observed with ELAHERE
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2023-- June 1, 2023 – ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the compensation committee of the Company’s Board of Directors (the “Compensation
WALTHAM, Mass. --(BUSINESS WIRE)--May 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, and Anna Berkenblit , Chief Medical Officer, will participate in a
WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common
Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the
WALTHAM, Mass. --(BUSINESS WIRE)--May 4, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $200 million of shares of its
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to Chemotherapy First Medicine to Demonstrate an Overall Survival Advantage in Platinum-Resistant Ovarian Cancer Submission of MAA in Europe and sBLA in US Anticipated in H2 2023 Conference Call to be Held at 8:00 AM